Recruiting NA Parkinson Disease

New treatment option for Parkinson Disease

Official title DetectFoG : Detection of Gait Freezing Episodes in Parkinsonian Patients Using Inertial Measurement Units

ClinicalTrials.gov ID: NCT05822258

What this study is testing

What it's testing
Parkinson's disease is the second most common neurodegenerative disease in the world. One of these manifestations is the freezing of gait (FOG) which affects 50 to 80% of Parkinsonian patients.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older

You may be able to join if

  • Patient over 18 years old
  • With Parkinson's disease according to the United Kingdom Brain Bank criteria
  • Presenting episodes of freezing of gait assessed on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS II - question...
  • Able to walk 30 meters independently
  • Affiliated to a social security scheme or beneficiary of such a scheme

You likely can't join if

  • Montreal Cognitive Assessment (MOCA) \< 20/30
  • Other neurological or orthopedic history that interferes with walking
  • Pregnant, parturient or breastfeeding women
  • Adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty
  • Persons undergoing psychiatric care, persons admitted to a health or social establishment for purposes other than research
  • Minors
See the full eligibility criteria
Who can join
  • Patient over 18 years old
  • With Parkinson's disease according to the United Kingdom Brain Bank criteria
  • Presenting episodes of freezing of gait assessed on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS II - question 13 with a score between 1 and 3 in order to have a patient walking...
  • Able to walk 30 meters independently
  • Affiliated to a social security scheme or beneficiary of such a scheme
  • Having signed a free and informed consent in writing
What rules you out
  • Montreal Cognitive Assessment (MOCA) \< 20/30
  • Other neurological or orthopedic history that interferes with walking
  • Pregnant, parturient or breastfeeding women
  • Adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty
  • Persons undergoing psychiatric care, persons admitted to a health or social establishment for purposes other than research
  • Minors
  • Persons unable to express their consent
  • Simultaneous participation in another research related to balance and/or walking

The study team makes the final eligibility decision.

Where it's taking place

  • Rennes, Brittany Region, France

Compensation & support

Compensation mentioned.

ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.

Questions & answers

Do participants get paid in this trial?

This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Rennes, Brittany Region, France. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.